Earnings, trial results, and acquisition activity were contributing factors to today's move higher for the stock market.
News & Analysis: Array BioPharma
Positive clinical trial results gave investors a reason to cheer.
ARRY earnings call for the period ending March 31, 2019.
Shares of this midcap biotech focused on developing cancer drugs have rocketed 63% higher in 2019.
Investors rushed to buy shares after the company detailed its latest progress.
ARRY earnings call for the period ending December 31, 2018.
Investors had more than one reason to feel good about Array BioPharma last month.
Here's what you need to know about one of the most successful drug discovery engines in biotech.
Why Array BioPharma, Deciphera Pharmaceuticals, and Blueprint Medicines Are Up by Double Digits Today
Shares of all three cancer-focused companies shot higher after one of their peers got bought out for a sizable premium.
Shares jump after the company reports an upbeat start to its fiscal year.